Data source: SignalRank.
For Prospective Investors
Access the World's top Venture Backed Companies
SignalRank is built to access top-decile venture-backed Series Bs by partnering with existing investors to fund their follow on rights. We select the top companies using a repeatable algorithmic process. Independent access to these companies for primary investments is normally impossible.
Portfolio (Count of companies)
0
Performance*
1.00x
* Performance since inception (May 2023).
Why SignalRank
Quality: proprietary algorithms target top-decile venture-backed Series B opportunities.
Access: network-enabled pro-rata access to high-potential companies backed by top-tier VCs.
Liquidity goal: single-investment exposure today with targeted listing pathway as AUM scales.
Model Evidence
Signal-led selection with measured outcomes
- 6.4x modeled five-year performance vs. 3.6x market.
- 31% probability of 5x+ MOIC company exposure at Series B vs. 10% for all Series Bs.
- 76% of Series B investments raising a Series C vs. 62% market.
- 30+ qualifying Series B investments per year target cohort.
How It Works
- Selection: SignalRank live model filters top-decile Series B candidates.
- Access: pro-rata financing via partner network and structured deal workflow.
- Returns: diversified portfolio construction designed for compounding outcomes.
SignalRank share participation is intended for accredited and qualified investors and is subject to KYC and accreditation review.
Investor Offering Highlights
- Entity: SignalRank Corporation (Delaware C Corporation).
- Instrument: Preferred stock.
- Minimum commitment: $1,000,000.
- Investment period: Ongoing; exits recycled into future cohorts.
- Target return: 5x MOIC per annual cohort over five years.
- Valuation: Set monthly by a valuation committee; annually audited externally.
- Expense ratio: 2.0% annualized cap today; target 0.50% at scale.
- Target liquidity: Direct listing once $100m+ AUM.
Become a SignalRank Investor
Start onboarding to determine fit and, once eligibility is confirmed, access full offering and subscription details.
Professional investors and clients only. This site is informational and does not constitute an offer to sell securities.